Extracranial Metastasis(顱外轉移)到底是什麼？
Extracranial Metastasis 顱外轉移 - ABSTRACT Background: Extracranial metastasis is a rare phenomenon of anaplastic oligoastrocytoma. [1] The patient's postoperative course was uneventful, and there was no recurrence or extracranial metastasis at 1. [2] Univariate analysis showed that DS-GPA score and extracranial metastasis were the independent factors of OS. [3] BACKGROUND Extracranial metastasis, mainly a feature of World Health Organization (WHO) grade III meningiomas, is only rarely reported in grade II meningiomas. [4] 014), presence of extracranial metastasis (p < 0. [5] The patient died 3 weeks after the diagnosis of extracranial metastasis. [6] Covariates included sex, age, KPS, BM lesions, extracranial metastasis, BM and lung tumor resection, chemotherapy, targeted therapy, and focal radiotherapy modalities. [7] Considering the biological obstacles that prevent glioblastomas from infiltrating outside of the CNS, it can be speculated that deposition of tumor cells into the blood stream or excision of the dura due to surgical interventions may attribute to extracranial metastasis. [8] 01), presence of extracranial metastasis (P=0. [9] Univariate analysis showed that control of primary lesions in chest, extracranial metastasis, KPS score, GPA grade, targeted therapy, brain metastasis diameter and peritumoral edema band diameter were the independent prognostic factors affecting the survival of patients. [10] Intracranial progression free survival (PFS) was statistically analyzed between different subgroups to find out the prognostic factors including gender, age, smoking history, extracranial metastasis, EGFR mutation type, size and number of intracranial lesions, carcino-embryonic antigen (CEA) level, lung-molGPA score and so on. [11] In the training set, EGFR/ALK positivity, Karnofsky performance score (KPS) score≥60 and absence of extracranial metastasis (ECM) independently predicted better OS. [12] 1%) had extracranial metastasis, and 14 patients (48. [13] Extracranial metastasis in a IDHwild type glioblastoma. [14] Extracranial metastasis of meningioma occurs extremely rare, only in about 0. [15] We report a case of IDH‐wild type glioblastoma with extracranial metastasis in submandibular region. [16] Background: Extracranial metastasis from intracranial meningioma is a very rare condition. [17] 001), and presence of extracranial metastasis (HR, 2. [18] We present a case of female patient with a known glioblastoma who had an extracranial metastasis on her left neck with complete Radiotherapy n Chemotherapy and survive more than 2 years. [19] Although GBM is the most common malignant brain tumor, extracranial metastasis is uncommon, and has been reported in only 2. [20] Number of BM, extracranial metastasis (ECM), and KPS independently affected OS/PFS in WT NSCLC BM, which was consistent with the known literature. [21] GS tumors often presented dural contact, while extracranial metastasis was only found in 1 patient. [22] Lung-mol GPA score was considered as a useful tool to estimate the prognosis; thus, the information of KPS score, extracranial metastasis, brain metastases numbers, and driver mutation status are essential to build a treatment strategy for synchronous brain metastasis from NSCLC. [23] Cox regression multivariate analysis identified EGFR mutation status, extracranial metastasis, primary tumor control, and prescribed margin dose as predictors of tumor control (p = 0. [24] Although most are benign in nature, malignant transformation and extracranial metastasis have been reported. [25]摘要背景：顱外轉移是間變性少突星形細胞瘤的一種罕見現象。 [1] 患者術後病程平穩，1日無復發或顱外轉移。 [2] 單因素分析顯示DS-GPA評分和顱外轉移是OS的獨立影響因素。 [3] 背景 顱外轉移是世界衛生組織 (WHO) III 級腦膜瘤的主要特徵，在 II 級腦膜瘤中很少報導。 [4] 014），存在顱外轉移（p<0. [5] 患者在診斷為顱外轉移後 3 週死亡。 [6] 協變量包括性別、年齡、KPS、BM 病變、顱外轉移、BM 和肺腫瘤切除、化療、靶向治療和局部放療方式。 [7] 考慮到阻止膠質母細胞瘤浸潤到 CNS 外部的生物學障礙，可以推測腫瘤細胞沉積到血流中或由於手術干預而切除硬腦膜可能歸因於顱外轉移。 [8] 01），存在顱外轉移（P=0. [9] 單因素分析顯示，胸部原發灶控制、顱外轉移、KPS評分、GPA分級、靶向治療、腦轉移直徑和瘤周水腫帶直徑是影響患者生存的獨立預後因素。 [10] 對不同亞組間的顱內無進展生存期（PFS）進行統計學分析，找出影響預後的因素包括性別、年齡、吸煙史、顱外轉移、EGFR突變類型、顱內病灶大小和數量、癌胚抗原（CEA）水平、肺-molGPA評分等。 [11] 在訓練集中，EGFR/ALK 陽性、Karnofsky 性能評分（KPS）評分≥60 和無顱外轉移（ECM）獨立預測更好的 OS。 [12] 1%) 有顱外轉移，14 名患者 (48. [13] IDHwild 型膠質母細胞瘤的顱外轉移。 [14] 腦膜瘤顱外轉移發生極為罕見，僅在0左右。 [15] 我們報告一例 IDH 野生型膠質母細胞瘤伴下頜下區顱外轉移。 [16] 背景：顱內腦膜瘤顱外轉移是一種非常罕見的疾病。 [17] 001）和顱外轉移（HR，2. [18] 我們介紹了一例已知為膠質母細胞瘤的女性患者，她的左頸部發生顱外轉移，接受完整的放療和化療並存活超過 2 年。 [19] 雖然 GBM 是最常見的惡性腦腫瘤，但顱外轉移並不常見，僅報導 2 例。 [20] BM 數量、顱外轉移 (ECM) 和 KPS 獨立影響 WT NSCLC BM 的 OS/PFS，這與已知文獻一致。 [21] GS腫瘤常出現硬腦膜接觸，而顱外轉移僅見於1例患者。 [22] Lung-mol GPA 評分被認為是評估預後的有用工具；因此，KPS評分、顱外轉移灶、腦轉移灶數量和驅動突變狀態的信息對於構建NSCLC同步腦轉移的治療策略至關重要。 [23] Cox 回歸多變量分析確定 EGFR 突變狀態、顱外轉移、原發腫瘤控制和規定的邊緣劑量作為腫瘤控制的預測因子（p = 0. [24] 儘管大多數是良性的，但也有惡性轉化和顱外轉移的報導。 [25]
extracranial metastasis tissue 顱外轉移組織
Here, we conducted comprehensive genomic and transcriptional analysis with paired primary tumor tissue (or extracranial metastasis tissue) and brain metastasis tissue using whole-exome sequencing (WES), mRNA-Seq and global methylation profiling. [1] Here, we conducted comprehensive genomic and transcriptional analysis with paired primary tumor tissue (or extracranial metastasis tissue) and brain metastasis tissue using whole-exome sequencing (WES), mRNA-Seq and global methylation profiling. [2]在這裡，我們使用全外顯子組測序 (WES)、mRNA-Seq 和全局甲基化分析對配對的原發性腫瘤組織（或顱外轉移組織）和腦轉移組織進行了全面的基因組和轉錄分析。 [1] 在這裡，我們使用全外顯子組測序 (WES)、mRNA-Seq 和全局甲基化分析對配對的原發性腫瘤組織（或顱外轉移組織）和腦轉移組織進行了全面的基因組和轉錄分析。 [2]